COMMUNIQUÉS West-GlobeNewswire

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
23/10/2025
Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ: PTHL) (the “Company”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related [...]
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
23/10/2025
DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
AVAVA Earns New FDA Clearance for the Treatment of Wrinkles
23/10/2025
The High-Energy Non-Ablative Platform Redefining What’s Possible in Skin Revitalization WALTHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- AVAVA, the powerful non-ablative energy platform powered by Focal Point [...]
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
23/10/2025
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. ( [...]
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
23/10/2025
TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report
23/10/2025
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, [...]
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
23/10/2025
Following its viral global premiere, ICAN and Del Bigtree release a response to media criticisms of the unpublished vaccinated-versus-unvaccinated study featured in the film AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE [...]
New Clinical Data Confirms Yomi® Robotic System Enhances Efficiency in Dental Implant Surgery
23/10/2025
MIAMI, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Neocis ® , the leader in robotic-assisted dental surgery, today announced new clinical data highlighting the significant efficiency benefits of its Yomi ® Robotic System, the [...]
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third [...]
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
23/10/2025
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly [...]
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
23/10/2025
LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern [...]
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
23/10/2025
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently [...]
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
23/10/2025
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 [...]
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
23/10/2025
TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat [...]
Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts
23/10/2025
Company honored by state’s Legislative Manufacturing Caucus for outstanding leadership and contributions to the manufacturing sector State -of-the-art production line is bringing in new clients, new projects, new [...]
Instinct Science and Cornell University Hospital for Animals Modernize Veterinary Care with Instinct Treatment Plan
23/10/2025
PHILADELPHIA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Instinct Science , a leading provider of clinical-grade software for veterinary hospitals, today announced that the Cornell University Hospital for Animals (CUHA) has [...]
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
23/10/2025
Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: €586.5 million, down 2.8% at CER 1 and on a like-for-like basis 2 , largely due to the fall in activity in France An increase in Q3 of 2.6% at [...]
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.
23/10/2025
Chiffre d’affaires au 30 septembre 2025 Retour de la croissance au 3 ème trimestre 2025 Chiffre d’affaires à 9 mois : 586,5 M€, en retrait de 2,8% à TCC 1 et périmètre comparable 2 , largement dû à la baisse de l’ [...]

Pages